Machine‐learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease

Documenti analoghi

• Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency
  di: Okan Cetin, et al.
  Pubblicazione: (2025)
• Correction to “Risk factors for severe infection and mortality in patients with COVID ‐19 in patients with multiple myeloma and AL amyloidosis”
  Pubblicazione: (2024)
• Timing and outcomes of second‐line therapy in the era of daratumumab‐based frontline therapy in AL amyloidosis
  di: Abdul‐Hamid Bazarbachi, et al.
  Pubblicazione: (2024)
• The Impact of Melphalan Conditioning and CD34+ Cell Dose and Schedule on Post‐Transplant Outcomes in AL Amyloidosis
  di: Eli Muchtar, et al.
  Pubblicazione: (2025)
• Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab‐Treated Patients
  di: George S. Mellgard, et al.
  Pubblicazione: (2026)